BACKGROUND AND AIMS The gastroprokinetic activities of ghrelin, the natural ligand of the growth hormone secretagogue receptor (GHS-R), prompted us to compare the effect of ghrelin with that of synthetic peptide (growth hormone releasing peptide 6 (GHRP-6)) and non-peptide (capromorelin) GHS-R agonists both in vivo and in vitro. METHODS In vivo, the dose dependent effects (1-150 nmol/kg) of g...

Background and aims: The gastroprokinetic activities of ghrelin, the natural ligand of the growth hormone secretagogue receptor (GHS-R), prompted us to compare the effect of ghrelin with that of synthetic peptide (growth hormone releasing peptide 6 (GHRP-6)) and non-peptide (capromorelin) GHS-R agonists both in vivo and in vitro. Methods: In vivo, the dose dependent effects (1–150 nmol/kg) of g...

The nuclear hormone receptor PPARγ is activated by several agonists, including members of the thiazolidinedione group of insulin sensitizers. Pleiotropic beneficial effects of these agonists, independent of their blood glucose-lowering effects, have recently been demonstrated in the vasculature. PPARγ agonists have been shown to lower blood pressure in animals and humans, perhaps by suppressing...

Small molecules that function as highly selective agonists and antagonists of cellular receptors comprise some of the most valuable therapeutic agents and molecular probes. A recent paper describes the design, synthesis, and evaluation of CO23, the first potent and specific agonist of thyroid hormone receptor-alpha (TRalpha), a member of the nuclear receptor (NR) superfamily of transcription fa...

Cancer is one of the leading causes mortality worldwide. PPAR modulators may hold great potential for management cancer patients. Indeed, PPARs are critical sensors and regulators lipid, they able to promote eNOS activation, regulate immunity inflammation response, affect proliferation differentiation cells. Cancer, a name given group diseases, characterized by multiple distinctive biological b...